As the extraordinary revenue phase driven by COVID-19 vaccines recedes, BioNTech is executing a deliberate strategic realignment. The company’s recent moves—a major acquisition, an upgraded financial forecast, and a refined research pipeline—aim to transition its business model. The central question for investors is whether this combination of new technology and a sharpened focus on cancer immunotherapies can revitalize its stock performance.
Revised Revenue Outlook Provides Near-Term Support
On November 3, 2025, BioNTech delivered a significant upgrade to its full-year revenue guidance. The company now anticipates sales between €2.6 billion and €2.8 billion, a substantial increase from its previous forecast of €1.7 billion to €2.2 billion.
This upward revision is attributed to a stronger-than-expected third quarter and stabilized demand for variant-adapted COVID-19 vaccines. Consequently, the anticipated decline in the vaccine business is proving less severe than initial projections at the start of the year. This provides a clearer fundamental basis for the equity, even as the shares remain under pressure, showing a year-to-date loss of approximately 29% and trading nearly 35% below their 52-week high.
CureVac Acquisition: Consolidating mRNA Leadership
A cornerstone of BioNTech’s new strategy is the now-formally completed acquisition of CureVac. The additional acceptance period concluded on December 18, 2025, with BioNTech securing approximately 86.75% of CureVac’s outstanding shares. A squeeze-out of the remaining minority shareholders is scheduled for January 2026.
This transaction consolidates key mRNA resources within Germany. The strategic rationale centers on two primary objectives: expanding production capacity for future vaccines and therapies, and streamlining the combined patent portfolio. For the market, the focus has shifted from the deal’s closure to the integration’s effectiveness. Investors are keenly watching for tangible contributions to operational efficiency and development speed in the upcoming fiscal year.
Should investors sell immediately? Or is it worth buying BioNTech?
Oncology Pipeline Takes Center Stage with BNT327
Increasingly, BioNTech’s valuation is being dictated by its oncology pipeline rather than its vaccine business. A key asset in this transition is BNT327 (pumitamig), a bispecific antibody candidate targeting PD‑L1 and VEGF‑A. This late-stage program is explicitly linked to the CureVac acquisition.
The integration of CureVac’s technology is intended to accelerate clinical timelines for prioritized projects like BNT327 from 2026 onward. This underscores a strategic shift away from a COVID-dependent model toward a broader portfolio of immunotherapies targeting cancer and other diseases.
Market Position and Forward-Looking Execution
From a technical perspective, the stock is trading just above its 52-week low and roughly 10% below its 200-day moving average—a chart pattern suggesting a potential basing formation rather than a clear directional trend. Fundamentally, the completion of the CureVac deal has removed a key execution risk, while the raised revenue guidance improves the expected cash flow position compared to earlier concerns.
Looking ahead to 2026, clinical execution moves to the forefront. Progress and key study readouts from the expanded oncology pipeline will be critical, with particular attention on further data and potential pivotal results for BNT327.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from December 24 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 24.
BioNTech: Buy or sell? Read more here...
